Immunotherapy Approaches in Cancer Treatment

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10296029" target="_blank" >RIV/00216208:11110/15:10296029 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023736:_____/15:00011371 RIV/00064165:_____/15:10296029

Výsledek na webu

<a href="http://dx.doi.org/10.2174/1389201016666150619114554" target="_blank" >http://dx.doi.org/10.2174/1389201016666150619114554</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/1389201016666150619114554" target="_blank" >10.2174/1389201016666150619114554</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Immunotherapy Approaches in Cancer Treatment

Popis výsledku v původním jazyce

Tumor immune surveillance paradigm presumes that most pre-malignant cells or early malignant lesions can be eliminated (or at least controlled) by cells of the immune system. A critical feature that distinguishes advanced tumors from early neoplastic lesions is their capability to evade immune control. As a consequence, vast majority of clinically evident (advanced) tumors are poorly immunogenic. The principle goal of immunotherapy is thus a resurrection of the patient's inefficient or suppressed immunesystem so that it would once again become capable of launching sustained cytolytic attacks against tumor cells, which would ideally result in total and permanent eradication of cancer. Such activation of patient's anticancer immunity, however, can be achieved by strikingly different ways. This current review discusses diverse innovative immunotherapy approaches, which in the last 20 years achieved miraculous successes in the ever-lasting battle against cancer, including cytokine-based i

Název v anglickém jazyce

Immunotherapy Approaches in Cancer Treatment

Popis výsledku anglicky

Tumor immune surveillance paradigm presumes that most pre-malignant cells or early malignant lesions can be eliminated (or at least controlled) by cells of the immune system. A critical feature that distinguishes advanced tumors from early neoplastic lesions is their capability to evade immune control. As a consequence, vast majority of clinically evident (advanced) tumors are poorly immunogenic. The principle goal of immunotherapy is thus a resurrection of the patient's inefficient or suppressed immunesystem so that it would once again become capable of launching sustained cytolytic attacks against tumor cells, which would ideally result in total and permanent eradication of cancer. Such activation of patient's anticancer immunity, however, can be achieved by strikingly different ways. This current review discusses diverse innovative immunotherapy approaches, which in the last 20 years achieved miraculous successes in the ever-lasting battle against cancer, including cytokine-based i

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Pharmaceutical Biotechnology

ISSN

1389-2010

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

AE - Spojené arabské emiráty

Počet stran výsledku

11

Strana od-do

771-781

Kód UT WoS článku

000358015000004

EID výsledku v databázi Scopus

—